SCHEMBL14320283

SCHEMBL14320283

COc1ccc(-c2nc(Nc3ccc(N4CCOCC4)cc3)c3[nH]ncc3n2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 8/20 0.58
JAK2 O60674 5/20 0.58
ABL1 P00519 3/20 0.55
NTRK1 P04629 3/20 0.55
YES1 P07947 3/20 0.55
KDR P35968 3/20 0.55
MAPK1 P28482 4/20 0.53
MAPT P10636 3/20 0.53
NPSR1 Q6W5P4 1/20 0.53
BTK Q06187 2/20 0.53
PIM1 P11309 2/20 0.53
HIPK1 Q86Z02 2/20 0.53
HTR2A P28223 1/20 0.51
HTR2C P28335 1/20 0.51
SRC P12931 1/20 0.50
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
LMNA P02545 1/20 0.46
POLB P06746 1/20 0.46
TSHR P16473 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14320440 0.90 JAK2 (0.55) SYKJAK2ABL1NTRK1YES1
SCHEMBL14320292 0.90 SYK (0.54) SYKJAK2ABL1NTRK1YES1
SCHEMBL14320593 0.89 SYK (0.59) SYKJAK2ABL1NTRK1YES1
SCHEMBL14320264 0.89 SYK (0.55) SYKJAK2ABL1NTRK1YES1
SCHEMBL14321256 0.89 SYK (0.60) SYKJAK2ABL1NTRK1YES1
SCHEMBL14320529 0.88 SYK (0.62) SYKJAK2MAPK1MAPTNPSR1
SCHEMBL14320402 0.88 SYK (0.58) SYKJAK2MAPK1MAPTNPSR1
SCHEMBL14320599 0.88 SYK (0.53) SYKJAK2ABL1NTRK1YES1
SCHEMBL14320869 0.87 SYK (0.75) SYKJAK2ABL1NTRK1YES1
SCHEMBL14320458 0.86 SYK (0.57) SYKJAK2MAPTNPSR1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US claimed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP claimed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US claimed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK SYK 11/4885JAK2 60/4885ABL1 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.